MAP3K7IP1 polyclonal, anti-human

Background:
MAP3K7IP1 was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli.

Other Names:
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, Mitogen-activated protein kinase kinase kinase 7-interacting protein 1, TGF-beta-activated kinase 1-binding protein 1, TAK1-binding protein 1, TAB1, MAP3K7IP1

Target/Specificity:
This MAP3K7IP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 416-445 amino acids from human MAP3K7IP1.

Antigen Region:
416-445

Antigen Type: Synthetic Peptide

Gene Name: TAB1
Gene ID: 10454
Primary Accession: Q15750
NCBI Accession: NP_006107.1;NP_705717.1
Other Accession: Q8CF89
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.